Arcus Biosciences (RCUS) Cash & Equivalents (2017 - 2026)

Arcus Biosciences' Cash & Equivalents history runs 10 years deep, the most recent figure standing at $201.0 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 4.69% year-over-year to $201.0 million; the TTM figure through Mar 2026 stood at $201.0 million (up 4.69% YoY), while the FY2025 annual figure was $222.0 million, up 48.0% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $201.0 million, down from $222.0 million in the prior quarter.
• The five-year high for Cash & Equivalents was $549.0 million in Q1 2022, with the low at $127.0 million in Q4 2023.
• The 5-year median for Cash & Equivalents is $206.0 million (2022), against an average of $224.6 million.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents plunged 56.65% in 2023, then soared 58.97% in 2025.
• Arcus Biosciences' Cash & Equivalents stood at $206.0 million in 2022, then plunged by 38.35% to $127.0 million in 2023, then increased by 18.11% to $150.0 million in 2024, then surged by 48.0% to $222.0 million in 2025, then decreased by 9.46% to $201.0 million in 2026.
• Business Quant data shows RCUS's Cash & Equivalents at $201.0 million in Q1 2026, $222.0 million in Q4 2025, and $238.0 million in Q3 2025.